These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12436915)

  • 1. Protein formulation and fill-finish operations.
    Patro SY; Freund E; Chang BS
    Biotechnol Annu Rev; 2002; 8():55-84. PubMed ID: 12436915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of Freezing and Freeze-Drying in Pharmaceutical Formulations.
    Izutsu KI
    Adv Exp Med Biol; 2018; 1081():371-383. PubMed ID: 30288720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current perspectives on stability of protein drug products during formulation, fill and finish operations.
    Rathore N; Rajan RS
    Biotechnol Prog; 2008; 24(3):504-14. PubMed ID: 18484778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fundamentals of freeze-drying.
    Nail SL; Jiang S; Chongprasert S; Knopp SA
    Pharm Biotechnol; 2002; 14():281-360. PubMed ID: 12189727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of rasburicase and physico-chemical characterization of the resulting injectable formulation.
    Bayol A; Breul T; Dupin P; Menegotto J; Aleman C; Duplaa H; Faure P; Bonnet MC; Bauer M
    Drug Dev Ind Pharm; 2004 Sep; 30(8):877-89. PubMed ID: 15521333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.
    Abdul-Fattah AM; Truong-Le V; Yee L; Pan E; Ao Y; Kalonia DS; Pikal MJ
    Pharm Res; 2007 Apr; 24(4):715-27. PubMed ID: 17372697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine as an Excipient for Protein Freeze-Drying: A Mini Review.
    Stärtzel P
    J Pharm Sci; 2018 Apr; 107(4):960-967. PubMed ID: 29183741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of stable lyophilized protein drug products.
    Remmele RL; Krishnan S; Callahan WJ
    Curr Pharm Biotechnol; 2012 Mar; 13(3):471-96. PubMed ID: 22283723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins III: collapse during storage at elevated temperatures.
    Schersch K; Betz O; Garidel P; Muehlau S; Bassarab S; Winter G
    Eur J Pharm Biopharm; 2013 Oct; 85(2):240-52. PubMed ID: 23727369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenge of drying method selection for protein pharmaceuticals: product quality implications.
    Abdul-Fattah AM; Kalonia DS; Pikal MJ
    J Pharm Sci; 2007 Aug; 96(8):1886-916. PubMed ID: 17252608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Freeze drying of nanosuspensions, 2: the role of the critical formulation temperature on stability of drug nanosuspensions and its practical implication on process design.
    Beirowski J; Inghelbrecht S; Arien A; Gieseler H
    J Pharm Sci; 2011 Oct; 100(10):4471-81. PubMed ID: 21607957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of manometric temperature measurement (MTM) and SMART freeze dryer technology for development of an optimized freeze-drying cycle.
    Gieseler H; Kramer T; Pikal MJ
    J Pharm Sci; 2007 Dec; 96(12):3402-18. PubMed ID: 17853427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact Of Excipient Variability On Drug Product Processing And Performance.
    Peng Soh JL; Liew CV; Sia Heng PW
    Curr Pharm Des; 2015; 21(40):5890-9. PubMed ID: 26446469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical spray freeze drying.
    Wanning S; Süverkrüp R; Lamprecht A
    Int J Pharm; 2015 Jul; 488(1-2):136-53. PubMed ID: 25900097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Freeze-drying of proteins: some emerging concerns.
    Roy I; Gupta MN
    Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):165-77. PubMed ID: 15032737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Instability of therapeutic proteins - An overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins.
    Butreddy A; Janga KY; Ajjarapu S; Sarabu S; Dudhipala N
    Int J Biol Macromol; 2021 Jan; 167():309-325. PubMed ID: 33275971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.